Comparative utility of urinary Megalin and Cystatin-c in identifying early renal damage in Type-2 Diabetes mellitus – A cross sectional study

  • Unique Paper ID: 173645
  • Volume: 11
  • Issue: 10
  • PageNo: 968-973
  • Abstract:
  • Kidney disease is a major complication of type-2 diabetes mellitus (T2DM) and a leading cause of end-stage renal disease. Early detection is crucial to prevent the progression of kidney damage. However, current markers such as microalbuminuria have low specificity, necessitating the exploration of novel biomarkers. Urinary megalin and cystatin-C have been proposed as potential early indicators of renal damage. The aim of the study is to evaluate urinary megalin and cystatin-C as biomarkers for early detection of renal damage in T2DM patients with different levels of albuminuria. This diagnostic evaluation study included 120 T2DM patients from a tertiary care hospital in South India, recruited between January and June 2023. Patients were grouped based on their urinary albumin-creatinine ratio (ACR): normoalbuminuria (ACR <30 mg/g) and microalbuminuria (ACR 30-299 mg/g). Urinary megalin and cystatin-c levels were measured using ELISA kits, and their associations with glycemic control, lipid profile, and other parameters were analyzed using Pearson’s correlation. The microalbuminuria group showed significantly lower urinary megalin (15.47 ± 4.99 pg/mL vs. 17.40 ± 5.11 pg/mL, p = 0.04) and cystatin-c levels (14.20 ± 7.87 ng/mL vs. 17.21 ± 7.60 ng/mL, p = 0.035) than the normoalbuminuria group. Urinary megalin and cystatin-c are promising early biomarkers for detecting renal damage in T2DM patients, potentially improving early diagnosis and outcomes.

Related Articles